Future Science OA is an esteemed open-access journal published by FUTURE SCI LTD, dedicated to advancing knowledge in the fields of biotechnology and medicine. Established in 2015, this journal has rapidly gained recognition within the scientific community, evidenced by its impressive ranking in both General Medicine (Rank #100/636, 84th percentile) and Biotechnology (Rank #145/311, 53rd percentile) as per Scopus metrics. With a Q2 category quartile in both fields as of 2023, Future Science OA provides a vital platform for researchers, professionals, and students to share groundbreaking research and innovative ideas. Notably, being an open-access journal allows for a wider dissemination of knowledge, ensuring equal access to high-quality research for practitioners and scholars alike. Based in the United Kingdom, Future Science OA is committed to fostering collaboration and dialogue within the scientific community, making it a cornerstone resource for advancing the future of the life sciences.

Med, an esteemed journal published by CELL PRESS, stands at the forefront of interdisciplinary medical research, making significant contributions to the field of Medicine since its inception in 2020. With an impressive Q1 ranking in the Medicine (miscellaneous) category and a notable 96th percentile ranking in General Medicine according to Scopus, this journal is dedicated to disseminating high-quality research that advances medical knowledge and practice. Med provides a platform where researchers, professionals, and students can share their findings and insights, fostering a collaborative environment that bridges various aspects of medicine. While offering a comprehensive body of research, Med is committed to promoting open communication within the scientific community, ensuring that valuable information is accessible to those who seek to enhance their understanding and application of medical science. With a strong presence in the United States and a global readership, Med is poised to influence the future of healthcare significantly.

The Journal of Skin Cancer, published by HINDAWI LTD, serves as a vital platform for advancing knowledge in the fields of Dermatology and Oncology. Established as an Open Access journal since 2011, it ensures wide dissemination of research findings, making significant contributions to the understanding of skin cancer pathogenesis, diagnosis, and treatment strategies. The journal holds a respectable rank within the academic community, reflected in its Q3 category placement in both Dermatology and Oncology for 2023, as well as its Scopus rankings, which place it in the 49th and 34th percentiles, respectively. Targeting an audience that includes researchers, healthcare professionals, and students, the Journal of Skin Cancer not only aims to present original research but also solicits reviews and case studies, thereby fostering a rich academic dialogue. With its headquarters located in London, England, the journal encourages global engagement and collaboration among scholars committed to improving outcomes in skin cancer.

Dermatologica Sinica, published by Wolters Kluwer Medknow Publications, is an esteemed open-access journal in the field of dermatology that has been disseminating critical research since its inception in 2005. With an E-ISSN of 2223-330X and an ISSN of 1027-8117, this journal presents a platform for researchers, clinicians, and students to share cutting-edge findings and advancements in dermatological science. As of 2023, it proudly ranks in the Q2 category of dermatology journals and holds a notable position at rank #62 out of 142 in the Scopus Medicine - Dermatology category, placing it in the 56th percentile for impact. The journal transitioned to an open-access model in 2016, enhancing accessibility and visibility for groundbreaking studies worldwide. With a commitment to fostering innovation in the dermatological community, Dermatologica Sinica aims to advance the understanding and treatment of skin diseases while encouraging scholarly dialogue among practitioners and researchers across the globe.

CURRENT OPINION IN INFECTIOUS DISEASES, published by Lippincott Williams & Wilkins, is a premier journal that focuses on the latest developments and understanding in the field of infectious diseases. With its ISSN 0951-7375 and E-ISSN 1473-6527, this journal has gained recognition for its pivotal role in advancing knowledge from 1988 to its current publications in 2024. Boasting an impressive Q1 ranking in both Infectious Diseases and the Medical Microbiology category, it holds a reputable position among the top journals in the field. The journal serves as an essential resource for researchers, professionals, and students alike, providing them with timely reviews, analyses, and perspectives that shape contemporary practice and policy. While lacking open access options, it ensures a critical examination of emerging trends and unique insights that foster informed discussions. With its consistently high impact factor, CURRENT OPINION IN INFECTIOUS DISEASES remains a vital platform for thought leaders and innovators navigating the complexities of infectious disease research.

Oncology Letters is a prominent academic journal dedicated to disseminating high-quality research in the fields of oncology and cancer research. Published by SPANDIDOS PUBL LTD and based in Greece, this journal has established a significant presence since its inception in 2010 and continues to contribute to the scientific community with a focus on both clinical and experimental oncology. Notably, it holds a respectable Q3 ranking in the categories of Cancer Research and Oncology as of 2023, highlighting its relevance and contribution to these critical fields. With a Scopus rank of #139/404 in Medicine – Oncology and #117/230 in Biochemistry, Genetics, and Molecular Biology – Cancer Research, Oncology Letters serves as a valuable platform for researchers, professionals, and students alike to explore emerging findings and innovative treatment approaches. Though it operates within a traditional subscription model, this journal prides itself on fostering accessible and impactful discourse in oncology, making it an essential resource for those committed to advancing cancer research and improving patient care.

Asian Biomedicine, published by WALTER DE GRUYTER GMBH, serves as a crucial platform for disseminating pioneering research in the field of biomedical sciences. Established in 2008, this journal has carved its niche in the landscape of academic publishing, concentrating on a diverse array of topics within biochemistry, genetics, and molecular biology, as well as medicine. Though it currently holds a Q4 ranking in its category, it is dedicated to fostering academic discussions and advancing knowledge among researchers, professionals, and students alike. While the journal features a variety of access options, it is committed to ensuring that its content remains relevant and impactful, with an emphasis on the latest developments and research trends. The editorial board encourages submissions that address pressing biomedical issues, thus empowering contributors to engage meaningfully with the scientific community. With a broad international scope and a focus on quality, Asian Biomedicine is poised to play an increasingly important role in the advancement of biomedical research in Asia and beyond.

Welcome to the Journal of Microbiology Immunology and Infection, a premier academic publication established in 1998 and now proudly owned by Elsevier Taiwan. As an Open Access journal since 2016, it provides unrestricted access to groundbreaking research in the fields of immunology, microbiology, and infectious diseases, making it an essential resource for researchers, practitioners, and students alike. The journal holds impressive rankings, including Q1 status in categories such as Infectious Diseases and Microbiology (medical), and a notable 92nd percentile in its Scopus ranking for Medicine - Infectious Diseases. With a dedicated focus on advancing knowledge and fostering collaboration within the scientific community, the Journal of Microbiology Immunology and Infection is committed to publishing high-impact research that significantly influences practice and policy in healthcare and life sciences. The journal is also recognized for its contribution to the ongoing dialogue surrounding contemporary issues in immunology and infection, positioning it as a vital platform for scholarly exchange and innovation.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Infectious Disease Reports is a premier open-access journal published by MDPI, dedicated to advancing the field of infectious diseases. Since its inception in 2009, this journal has established itself as a significant platform for disseminating cutting-edge research, reviews, and case studies, critical for global health. With a commendable Q2 ranking in the category of Infectious Diseases and a Scopus rank of #140 out of 344, it is recognized for its impactful contributions to medical research, holding a 59th percentile in its field. The journal aims to provide comprehensive insights into various dimensions of infectious diseases, ranging from epidemiology to novel treatment modalities. As an open-access publication, Infectious Disease Reports ensures that its articles are freely available to a wide audience, fostering collaborative efforts among researchers, healthcare professionals, and students worldwide. With its ongoing commitment to excellence, the journal plays an essential role in shaping the future of infectious disease research.